{"id":"https://openalex.org/W2134178274","doi":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","title":"Pharmacokinetic\u2010pharmacodynamic interaction between the COMT inhibitor tolcapone and single\u2010dose levodopa.","display_name":"Pharmacokinetic\u2010pharmacodynamic interaction between the COMT inhibitor tolcapone and single\u2010dose levodopa.","publication_year":1995,"publication_date":"1995-09-01","ids":{"openalex":"https://openalex.org/W2134178274","doi":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","mag":"2134178274","pmid":"https://pubmed.ncbi.nlm.nih.gov/8527287","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1365105"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.1995.tb05781.x","doi":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1995.tb05781.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1995.tb05781.x","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058093690","display_name":"Jasper Dingemanse","orcid":"https://orcid.org/0000-0002-4083-5817","observed_orcids":["https://orcid.org/0000-0002-4083-5817"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"J. Dingemanse","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110032422","display_name":"Karin M. Jorga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"K. Jorga","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018337880","display_name":"Gerhard Z\u00fcrcher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"G. Zurcher","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109307026","display_name":"Monique Schmitt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"M. Schmitt","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111626346","display_name":"Greg Sedek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"G. Sedek","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110437442","display_name":"M. Da Prada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"M. Da Prada","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071530067","display_name":"P. van Brummelen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"P. Van Brummelen","raw_affiliation_strings":["Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I118019719"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":8.0198,"has_fulltext":true,"cited_by_count":114,"citation_normalized_percentile":{"value":0.98078969,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"40","issue":"3","first_page":"253","last_page":"262"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.6474999785423279,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.6474999785423279,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.32499998807907104,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11027","display_name":"Metabolism and Genetic Disorders","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tolcapone","display_name":"tolcapone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":0.9940000176429749},{"id":"https://openalex.org/keywords/catechol-o-methyltransferase-inhibition","display_name":"catechol-O-methyltransferase inhibition","score":0.9269999861717224},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-interaction","display_name":"pharmacokinetic-pharmacodynamic interaction","score":0.9380000233650208},{"id":"https://openalex.org/keywords/levodopa-pharmacokinetics","display_name":"levodopa pharmacokinetics","score":0.871999979019165},{"id":"https://openalex.org/keywords/dose-dependent-effects","display_name":"dose-dependent effects","score":0.47699999809265137},{"id":"https://openalex.org/keywords/dopaminergic-stimulation","display_name":"dopaminergic stimulation","score":0.6589999794960022},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.8640000224113464}],"concepts":[{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.831331729888916},{"id":"https://openalex.org/C185361966","wikidata":"https://www.wikidata.org/wiki/Q94291140","display_name":"Catechol-O-methyl transferase","level":4,"score":0.8288047313690186},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8004326820373535},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6775094270706177},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6091084480285645},{"id":"https://openalex.org/C2776976799","wikidata":"https://www.wikidata.org/wiki/Q416444","display_name":"Entacapone","level":5,"score":0.5945494174957275},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5580483078956604},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5251390933990479},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.49319571256637573},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.43622681498527527},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.36706286668777466},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2902042865753174},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.16692867875099182},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.09938353300094604},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.058588385581970215},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077867","descriptor_name":"Tolcapone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001577","descriptor_name":"Benzophenones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001577","descriptor_name":"Benzophenones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002394","descriptor_name":"Catechol O-Methyltransferase","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009596","descriptor_name":"Nitrophenols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010599","descriptor_name":"Pharmacokinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014838","descriptor_name":"Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1365-2125.1995.tb05781.x","doi":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1995.tb05781.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1365105","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1365105","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:8527287","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8527287","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2125.1995.tb05781.x","doi":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1995.tb05781.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1995.tb05781.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2134178274.pdf","grobid_xml":"https://content.openalex.org/works/W2134178274.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W245866583","https://openalex.org/W1506736245","https://openalex.org/W1561054290","https://openalex.org/W1965754554","https://openalex.org/W1980384054","https://openalex.org/W1982924711","https://openalex.org/W1988277995","https://openalex.org/W2014601915","https://openalex.org/W2020613687","https://openalex.org/W2027221223","https://openalex.org/W2034816810","https://openalex.org/W2051557976","https://openalex.org/W2057232876","https://openalex.org/W2058662668","https://openalex.org/W2067324181","https://openalex.org/W2069981464","https://openalex.org/W2080126151","https://openalex.org/W2084633854","https://openalex.org/W2085965461","https://openalex.org/W2089182747","https://openalex.org/W2089597021","https://openalex.org/W2118896395","https://openalex.org/W2144727555","https://openalex.org/W2227046083","https://openalex.org/W2239722532","https://openalex.org/W2323830726","https://openalex.org/W2330445375","https://openalex.org/W2407776342","https://openalex.org/W2411729407","https://openalex.org/W2416937170","https://openalex.org/W2502670554","https://openalex.org/W3215454188","https://openalex.org/W4210995338","https://openalex.org/W4246076186"],"related_works":["https://openalex.org/W1985417541","https://openalex.org/W2009708719","https://openalex.org/W2043729686","https://openalex.org/W2113689256","https://openalex.org/W2036056358","https://openalex.org/W2051557976","https://openalex.org/W1965714500","https://openalex.org/W1991152368","https://openalex.org/W1998323566","https://openalex.org/W2016013480"],"abstract_inverted_index":{"1.":[0],"Single":[1],"oral":[2],"doses":[3],"of":[4,20,28,41,76,90,104,117,127,146,160,166,189,194,201],"the":[5,102,108,111,143],"catechol-O-methyltransferase":[6],"(COMT)":[7],"inhibitor":[8],"tolcapone":[9,190],"(10-800":[10],"mg)":[11],"or":[12],"placebo":[13],"were":[14,50,72,122],"administered":[15],"simultaneously":[16],"with":[17,54,97,192,206],"a":[18,34,85,98,125,158,164],"dose":[19,68,126],"levodopa/benserazide":[21],"100/25":[22],"mg":[23,130],"to":[24,176],"seven":[25],"sequential":[26],"groups":[27],"six":[29],"healthy":[30],"male":[31],"subjects":[32],"in":[33,52,57,79,93,95,101,174,197,208],"two-way":[35],"crossover":[36],"study.":[37],"2.":[38],"Plasma":[39,187],"concentrations":[40,188],"tolcapone,":[42],"its":[43],"metabolite":[44],"3-O-methyltolcapone,":[45],"levodopa":[46,209],"and":[47,70,87,114,153,163,199],"3-O-methyldopa":[48],"(3-OMD)":[49],"determined":[51],"conjunction":[53],"COMT":[55,91,195],"activity":[56,92,196],"erythrocytes.":[58],"3.":[59],"The":[60,119,137,169],"drug":[61,138,170],"combination":[62],"was":[63,150,180],"well":[64],"tolerated":[65],"at":[66,124,183],"all":[67],"levels":[69],"there":[71],"no":[73,140],"signs":[74],"indicative":[75],"an":[77],"increase":[78],"dopaminergic":[80],"stimulation.":[81],"4.":[82],"Tolcapone":[83,106,149],"caused":[84],"rapid":[86],"reversible":[88],"inhibition":[89,193],"erythrocytes":[94,198],"parallel":[96],"dose-dependent":[99],"decrease":[100],"formation":[103,179],"3-OMD.":[105],"increased":[107,134],"area":[109],"under":[110],"concentration-time":[112],"curve":[113],"elimination":[115],"half-life":[116],"levodopa.":[118,147],"maximum":[120,144],"effects":[121],"obtained":[123],"about":[128],"200":[129],"when":[131],"both":[132],"parameters":[133],"approximately":[135],"twofold.":[136],"had":[139],"influence":[141],"on":[142,156],"concentration":[145],"5.":[148],"rapidly":[151],"absorbed":[152],"eliminated":[154],"with,":[155],"average,":[157],"tmax":[159],"1.5":[161],"h":[162],"t1/2":[165],"2.3":[167],"h.":[168],"showed":[171],"dose-proportional":[172],"pharmacokinetics,":[173],"contrast":[175],"3-O-methyltolcapone":[177],"whose":[178],"relatively":[181],"decreased":[182],"higher":[184],"doses.":[185],"6.":[186],"correlated":[191],"suppression":[200],"3-OMD":[202],"levels,":[203],"but":[204],"not":[205],"changes":[207],"pharmacokinetics.":[210]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}